Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Armata Pharmaceuticals, Inc. (ARMP) Net Income towards Common Stockholders (2016 - 2018)

Armata Pharmaceuticals' Net Income towards Common Stockholders history spans 6 years, with the latest figure at -$8.9 million for Q4 2018.

  • For Q4 2018, Net Income towards Common Stockholders fell 282.49% year-over-year to -$8.9 million; the TTM value through Dec 2018 reached -$16.7 million, down 16.02%, while the annual FY2024 figure was -$53.2 million, 22.71% down from the prior year.
  • Net Income towards Common Stockholders for Q4 2018 was -$8.9 million at Armata Pharmaceuticals, down from -$1.6 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $14.2 million in Q3 2014 and bottomed at -$14.8 million in Q1 2015.
  • The 5-year median for Net Income towards Common Stockholders is -$3.1 million (2018), against an average of -$2.2 million.
  • The largest YoY upside for Net Income towards Common Stockholders was 2393.01% in 2014 against a maximum downside of 606.44% in 2014.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at $5.7 million in 2014, then tumbled by 130.2% to -$1.7 million in 2015, then tumbled by 451.04% to -$9.5 million in 2016, then soared by 75.47% to -$2.3 million in 2017, then tumbled by 282.49% to -$8.9 million in 2018.
  • Per Business Quant, the three most recent readings for ARMP's Net Income towards Common Stockholders are -$8.9 million (Q4 2018), -$1.6 million (Q3 2018), and -$3.0 million (Q2 2018).